

# Drug Policy

<b>Policy:</b>	<b>201012</b>	<b>Initial Effective Date: 12/22/2010</b>  <b>Annual Review Date: 06/18/2024</b>  <b>Last Revised Date: 11/21/2024</b>
<b>Code(s):</b>	<b>HCPCS J3357, Q5137, J3590</b>	
<b>SUBJECT:</b>	<b>Ustekinumab Subcutaneous Injection</b> <ul style="list-style-type: none"> <li>• <b>Stelara™ (ustekinumab)</b></li> <li>• <b>Selarsdi (ustekinumab-aekn)</b></li> <li>• <b>Wezlana (ustekinumab-auub)</b></li> <li>• <b>Pyzchiva (ustekinumab-ttwe)</b></li> </ul>	

Subject to Site of Care

**Prior approval is required for some or all of the procedure codes listed in this Corporate Medical Policy.**

Initial and renewal requests for the medication(s) listed in this policy are subject to site of care management. When billed under the medical benefit, administration of the medication will be restricted to a non-hospital facility-based location (i.e., home infusion provider, provider’s office, free-standing ambulatory infusion center) unless the member meets the site of care exception criteria. To view the exception criteria and a list of medications subject to site of care management please [click here](#).

**Overview**

Stelara is indicated for the treatment of those ≥ 6 years of age with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, for adult patients ≥ 18 years of age with active psoriatic arthritis (PsA) alone or in combination with methotrexate (MTX), and for moderate to severe active Crohn’s Disease, in patients who have failed or were intolerant to immunomodulators or corticosteroids, but never failed a tumor necrosis factor inhibitor (TNFi), or in patients who failed or were intolerant to at least on TNFi. Stelara is also indicated for the treatment of patients ≥ 18 years of age with moderate to severe active Ulcerative Colitis. Stelara is a human immunoglobulin G (IgG) 1κ monoclonal antibody against the p40 subunit of the interleukin (IL)-12 and IL-23 cytokines, which are involved in inflammatory and immune responses. It is administered by subcutaneous (SC) injection under the supervision of a physician, although with proper training patients may self-inject.

Stelara for intravenous IV infusion is indicated for the treatment of adults ≥ 18 years of age with moderate to severe active Crohn’s disease, in patients who have failed or were intolerant to immunomodulators or corticosteroids, but never failed a tumor necrosis factor inhibitor (TNFi), or in patients who failed or were intolerant to at least one TNFi. It is a human immunoglobulin G (IgG) 1κ monoclonal antibody against the p40 subunit of the interleukin (IL)-12 and IL-23 cytokines, which are involved in inflammatory and immune responses. In Crohn’s disease, a single weight-based dose is administered by IV infusion. For both Ulcerative Colitis and Crohn’s Disease, a single, weight-based induction dose with the IV product is administered, followed by the recommended maintenance is Stelara for subcutaneous (SC) injection, given as a 90 mg SC injection administered 8 weeks after the initial IV dose, then once every 8 weeks (Q8W) thereafter.

# Drug Policy

## POLICY STATEMENT

This policy involves the use of ustekinumab. Prior authorization is recommended for medical benefit coverage of ustekinumab. Approval is recommended for those who meet the conditions of coverage in the **Criteria, Dosing, Initial/Extended Approval, Duration of Therapy, and Labs/Diagnostics** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria and Waste Management section. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

Because of the specialized skills required for evaluation and diagnosis of patients treated with ustekinumab as well as the monitoring required for AEs and long-term efficacy, initial approval requires ustekinumab be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below. Ustekinumab SC is subject to the **Inflammatory Conditions Care Value Step Therapy**.

## Food and Drug Administration (FDA)-Approved Indications

### 1. Plaque Psoriasis (Stelara, Wezlana, Selarsdi, Pyzchiva):

Note: If the 90 mg syringe is requested, approve if the patient meets one of the following:

- patient weighs > 100 kg; OR
- patient is currently receiving the 90 mg syringe; OR
- patient has received standard dosing with the 45 mg syringe/vial for at least 3 months with inadequate efficacy.

#### I. Initial Therapy. Approve for 3 months if the patient meets ALL of the following criteria (i, ii AND iii):

- i. Patient meets ONE of the following conditions (a or b or c):
  - a) Patient has tried at least one of the following agents for at least 3 months for plaque psoriasis: an oral therapy for psoriasis (e.g., MTX, cyclosporine, acitretin tablets; oral methoxsalen plus ultraviolet A light (PUVA)); or
  - b) The patient has tried ONE biologic disease-modifying antirheumatic drug (DMARD) for at least 3 months [Refer to Appendix A for examples] OR
  - c) Patient has a contraindication to one oral agent for psoriasis such as MTX, as determined by the prescribing physician; AND
- ii. Patient is 6 years of age or older; AND
- iii. The medication is prescribed by or in consultation with a dermatologist.

#### II. Patient is Currently Receiving Stelara, Wezlana or Selarsdi. Approve if the patient has had a beneficial response as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to therapy.

### Dosing in Plaque Psoriasis.

- Adult Subcutaneous Recommended Dosage

Weight Range (kilograms)	Recommended Dosage
--------------------------	--------------------

# Drug Policy

Less than or equal to 100 kg	45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks
greater than 100 kg	90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks

- **Pediatric (6 to 17 years old) Subcutaneous Recommended Dosage**
  - Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.

Weight Range (kilograms)	Recommended Dosage
Less than 60 kg (Not applicable to Slearsdi or Pyzchiva)	0.75 mg/kg
60 kg to 100 kg	45 mg
Greater than 100 kg	90 mg

### **Approval Duration**

Initial Approval = 3 months (90 days)

Re-authorization = 1 year (365 days)

## **2. Psoriatic Arthritis (PsA) (Stelara, Wezlana, Selarsdi, Pyzchiva):**

**Note:** If the 90 mg syringe is requested, approve if the patient meets one of the following:

- patient has moderate to severe plaque psoriasis AND weighs > 100 kg; OR
- patient is currently receiving the 90 mg syringe; OR
- patient has received standard dosing with the 45 mg syringe/vial for at least 3 months with inadequate efficacy.

**I. Initial Therapy.** Approve for 6 months if the medication is prescribed by or in consultation with a rheumatologist or a dermatologist.

**II. Patient is Currently Receiving Stelara, Wezlana, Selarsdi.** Approve for 1 year if the patient has had a beneficial response (e.g., less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improvements in acute phase reactants [for example, C-reactive protein]), as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to therapy.

### **Dosing in Psoriatic Arthritis.**

#### • **Adult Subcutaneous Recommended Dosage**

- The recommended dosage is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks
- For patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg, The recommended dosage is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks

# Drug Policy

- Pediatric (6 to 17 years old) Subcutaneous Recommended Dosage
  - Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter.

Weight Range (kilograms)	Recommended Dosage
Less than 60 kg (Not applicable to Slearsdi or Pyszchiva)	0.75 mg/kg
60 kg to 100 kg	45 mg
Greater than 100 kg with co-existent moderate-to-severe plaque psoriasis	90 mg

### Approval Duration

Initial Approval = 6 months (180 days)

Re-authorization = 1 year (365 days)

### 3. Crohn's Disease in an Adult, SQ maintenance therapy (Stelara, Wezlana, Pyszchiva):

A) Initial SC Therapy. Approve for 6 months if the patient meets the following criteria (i, ii, iii and iv):

- i. The patient meets one of the following conditions (a, b or c):
  - a. The patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated in this patient; OR
  - b. The patient has tried one conventional systemic therapy for Crohn's disease for at least 3 months (e.g., azathioprine, 6-mercaptopurine, or methotrexate [MTX]); OR
  - c. The patient has tried ONE biologic disease-modifying antirheumatic drug (DMARD) [Refer to Appendix A for examples] AND
- ii. The medication is prescribed by or in consultation with a gastroenterologist.
- iii. The patient is 18 years of age or older; AND
- iv. The patient has received a single induction dose with Stelara or Wezlana IV within 2 months of initiating therapy with Stelara or Wezlana SC;

B) Patients Currently Receiving Stelara or Wezlana (IV or SC). Approve for 1 year if the patient has had a response, as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to therapy.

Note: Patients with fistulizing Crohn's disease or Crohn's disease of the ileal pouch must meet the above criteria for Crohn's disease in adults.

### Dosing in Crohn's Disease, SQ maintenance therapy

- Adult Subcutaneous Recommended Dosage

The recommended dosage is 90 mg administered subcutaneously 8 weeks after the initial intravenous dose, followed by 90 mg administered subcutaneously every 8 weeks thereafter.

### Approval Duration

Initial Approval = 6 months (180 days)

Re-authorization = 1 year (365 days)

# Drug Policy

## 5. Ulcerative Colitis, SQ maintenance therapy (Stelara, Wezlana, Pyzchiva):

**III.** Initial Therapy. Approve or 6 months if the patient meets the following criteria (A, B, C, and D):

- A) The patient is 18 years of age or older; AND
- B) The patient has received a single induction dose with Stelara IV or Wezlana IV within 2 months of initiating therapy; AND
- C) The patient has had a trial of one systemic agent for ulcerative colitis.  
Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone. A trial of a biologic (e.g., an adalimumab product, an infliximab product, Simponi® [golimumab for SC injection], or Entyvio [vedolizumab injection]) also counts as a trial of one systemic agent for UC; AND
- D) The agent is prescribed by or in consultation with a gastroenterologist.

**IV.** Continuation of Therapy: Approve for 1 year if the patient has had a response to therapy, as determined by the prescriber. Examples of a response to therapy include decreased stool frequency or rectal bleeding.

### Dosing in Ulcerative Colitis, SQ maintenance therapy

- Adult Subcutaneous Recommended Dosage

The recommended dosage is 90 mg administered subcutaneously 8 weeks after the initial intravenous dose, followed by 90 mg administered subcutaneously every 8 weeks thereafter.

### Approval Duration

Initial Approval = 6 months (180 days)

Re-authorization = 1 year (365 days)

### **CRITERIA NOT RECOMMENDED FOR APPROVAL:**

Ustekinumab has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

- 1. Concurrent Biologic Therapy.** Ustekinumab should not be administered in combination with another biologic agent for an inflammatory condition (e.g., TNF antagonists [Cimzia® {certolizumab pegol for SC injection}, Enbrel, Humira, Remicade, or Simponi], or Kineret® [anakinra for SC injection]). Combination therapy with two biologic agents is not recommended due to a higher rate of adverse effects with combinations and lack of additive efficacy.<sup>6</sup>
- 2. Ankylosing Spondylitis (AS).** There is a published proof-of-concept trial evaluating Stelara in AS (TOPAS – UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis).<sup>12</sup> TOPAS was a prospective, open-label study evaluating Stelara 90 mg at Week 0, 4, and 16 in patients (n = 20) with AS. After Week 16, patients were followed through Week 28. Patients who previously failed to respond to TNF blockers were excluded, but patients who discontinued a TNF for reasons other than lack of efficacy were allowed to enroll. The primary endpoint was a 40% improvement in disease activity at Week 24 according to the ASAS criteria (ASAS40). Efficacy analysis was completed in the intent-to-treat (ITT) population which included all patients who received at least one dose of Stelara. In all, 65% of patients (95% confidence interval [CI]: 41%, 85%; n = 13/20) achieved an ASAS40 response at Week 24. There



# Drug Policy

was at least a 50% improvement of the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) achieved by 55% of patients (95% CI: 32%, 77%; n = 11/20); improvement in other secondary endpoints were also noted. However, enthesitis (measured by MASES [Maastricht AS Entheses Score] and SPARCC [SPondyloArthritis Research Consortium of Canada] enthesitis indices) and the number of swollen joints were not significantly improved at Week 24. There was a significant reduction of active inflammation on magnetic resonance imaging (MRI) at Week 24 compared with baseline in sacroiliac joints.

- 3. Concurrent use with Otezla.** No evidence to suggest that combination use of Otezla with ustekinumab is superior to monotherapy.
- 4.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## Documentation Requirements:

The Company reserves the right to request additional documentation and to deny reimbursement when it has determined that the services performed were not medically necessary, investigational and/or a pattern of practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

## REFERENCES

- Stelara® injection [prescribing information]. Horsham, PA: Centocor Ortho Biotech; November 2019.
- WEZLANA™ (ustekinumab-auub). Package insert. Amgen Inc; October 2023
- SELARSDI™ (ustekinumab-aekn) injection, for subcutaneous use. Package insert. Alvotech USA Inc; April 2024
- Pyzchiva [package insert]. Yeonsu-gu, Incheon; Samsung Bioepis Co., Ltd.; June 2024. Accessed July 2024.
- Leonardi C, Kimball AB, Papp KA, et al, for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with psoriasis: 76-weeks results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*. 2008;371:1665-1674.
- Papp KA, Langley RG, Lebwohl M, et al, for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52 week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet*. 2008;371:1675-1684.
- Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. *Arch Dermatol*. 2012;148(1):95-102.
- McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. *Lancet*. 2013;382(9894):780-789.
- Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis*. 2013;72 Suppl 2:ii2-34.
- Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. *Gastroenterology*. 2008;135:1130-1141.

# Drug Policy

- Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *N Engl J Med.* 2012;367(16):1519-1528.
- Segal BM, Constantinescu CS, Raychauri A, et al, on behalf of the ustekinumab MS investigators. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. *Lancet Neurol.* 2008;7:796-804.
- Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Ann Rheum Dis.* 2012;71(1):4-12.
- Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. *Ann Rheum Dis.* 2009;68(9):1387-1394.
- Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). *Ann Rheum Dis.* 2014;73(5):817-823.
- Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease - the McGill experience. *J Crohns Colitis.* 2014;8(11):1516-2152.

**Prior approval is required for HCPCS Code J3357, Q5137, J3590**

## Appendix A

	Mechanism of Action	Examples of Inflammatory Indications*
<b>Biologics</b>		
<b>Adalimumab SC Products</b> (Humira®, biosimilars)	Inhibition of TNF	AS, CD, JIA, PsO, PsA, RA, UC
<b>Cimzia®</b> (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, nr-axSpA, PsO, PsA, RA
<b>Etanercept SC Products</b> (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA
<b>Infliximab IV Products</b> (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
<b>Simponi®, Simponi® Aria™</b> (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC IV formulation: AS, PJIA, PsA, RA
<b>Actemra®</b> (tocilizumab IV infusion, tocilizumab SC injection)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA IV formulation: PJIA, RA, SJIA
<b>Kezara®</b> (sarilumab SC injection)	Inhibition of IL-6	RA
<b>Orencia®</b> (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PSA, RA IV formulation: JIA, PsA, RA
<b>Rituximab IV Products</b> (Rituxan®, biosimilars)	CD20-directed cytolytic antibody	RA
<b>Kineret®</b> (anakinra SC injection)	Inhibition of IL-1	JIA <sup>^</sup> , RA
<b>Stelara®</b> (ustekinumab SC injection, ustekinumab IV infusion)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC IV formulation: CD, UC
<b>Siliq™</b> (brodalumab SC injection)	Inhibition of IL-17	PsO
<b>Cosentyx®</b> (secukinumab SC injection)	Inhibition of IL-17A	AS, ERA, nr-axSpA, PsO, PsA
<b>Taltz®</b> (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
<b>Ilumya™</b> (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
	Inhibition of IL-23	SC formulation: CD, PSA, PsO

# Drug Policy

<b>Skyrizi®</b> (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)		IV formulation: CD
<b>Tremfya™</b> (guselkumab SC injection)	Inhibition of IL-23	PsO
<b>Entyvio™</b> (vedolizumab IV infusion)	Integrin receptor antagonist	CD, UC
<b>Oral Therapies/Targeted Synthetic DMARDs</b>		
<b>Otezla®</b> (apremilast tablets)	Inhibition of PDE4	PsO, PsA
<b>Cibinqo™</b> (abrocitinib tablets)	Inhibition of JAK pathways	AD
<b>Olumiant®</b> (baricitinib tablets)	Inhibition of JAK pathways	RA
<b>Rinvoq®</b> (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, AS, nr-axSpA, RA, PsA, UC
<b>Sotyktu™</b> (deucravacitinib tablets)	Inhibition of TYK2	PsO
<b>Xeljanz®</b> (tofacitinib tablets)	Inhibition of JAK pathways	RA, PJIA, PsA, UC
<b>Xeljanz® XR</b> (tofacitinib extended-release tablets)	Inhibition of JAK pathways	RA, PsA, UC

\* Not an all-inclusive list of indications (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJIA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis; DMARD – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; TYK2 – Tyrosine kinase 2.